Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Piecing Together The Interoperability Puzzle: Q&A With Julian Goldman

This article was originally published in The Gray Sheet

Executive Summary

In a recent interview with “The Gray Sheet,” the founding director of the Medical Device Interoperability Program describes an ongoing effort to establish a clearer FDA pathway for devices designed to seamlessly communicate with other products, even those made by different manufacturers.

You may also be interested in...



J&J’s Sedasys Sedation System Now “Approvable,” Though Some Questions Remain

Outstanding FDA questions pertain to follow-up data, user training and “post-market observance and those sorts of things,” CFO Dominic Caruso told investors during the firm’s first-quarter earnings call April 17.

FDA Medical Device Data Systems Rule Still Raising Questions

While a mid-May deadline has come and gone for makers of "medical device data systems" to register their products with FDA, many are still wondering whether their offerings fall within the agency’s definition of the newly classified device category.

"Plug And Play" Medical Systems Raise Complicated Regulatory Questions

FDA, device makers and others are struggling to identify the best way to regulate "interoperable" medical systems - such as an iPhone that receives blood glucose data - with some suggesting that a separate classification scheme might be needed

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031857

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel